- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.11.24 | Aelis Farma Announces the Positive Results of Its Clinical Phase 1/2 Study with AEF0217 in Young Adults With Down Syndrome | 270 | Business Wire | The CB1-SSi AEF0217 successfully met the safety (primary), pharmacokinetic (secondary) and efficacy (secondary and exploratory) objectives of this phase 1/2 performed in young adults with Down... ► Artikel lesen | |
| 26.09.24 | Aelis Farma: Availability of the 2024 Half-year Financial Report | 224 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 ticker: AELIS), a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, today announces that its half-year... ► Artikel lesen | |
| 25.09.24 | Aelis Farma Announces Half-year Financial Results for 2024 and Provides Corporate and Development Update | 293 | Business Wire | A solid cash position of €12.6 million at June 30, 2024, not including the gross amount of €4.5 million share offering which occurred at the end of July and other non-dilutive financing currently... ► Artikel lesen | |
| 04.09.24 | Indivior reports "disappointing" results for study with Aelis Farma | 6 | Alliance News | ||
| 04.09.24 | Indivior PLC: Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder | 394 | PR Newswire | THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN... ► Artikel lesen | |
| AELIS FARMA Aktie jetzt für 0€ handeln | |||||
| 04.09.24 | Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD) | 348 | Business Wire | The main objective of this phase 2B study was to demonstrate that AEF0117 reduces cannabis use and to determine the endpoints as well as the optimal dosage of AEF0117 for use in future studies.... ► Artikel lesen | |
| 31.07.24 | Aelis Farma Announces the Successful Completion of Its Reserved Offering for a Total Gross Amount of €4.5 Million | 415 | Business Wire | Regulatory News:
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS the "Company"), a... ► Artikel lesen | |
| 30.07.24 | Aelis Farma: Launch of a Reserved Offering of Approximately €5 Million | 461 | Business Wire | NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA AND JAPAN Launch of a Reserved Offering of new shares for c. €5 million aimed at categories... ► Artikel lesen | |
| 24.06.24 | Aelis Farma: Availability of the Description of the Share Buyback Program | 261 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS) (Paris:AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces... ► Artikel lesen | |
| 04.06.24 | Results of Aelis Farma Combined General Meeting of June 4, 2024 | 346 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases announces that all... ► Artikel lesen | |
| 14.05.24 | Aelis Farma: Combined General Meeting of June 4, 2024: Availability of Preparatory Documents and Participation and Voting Procedures | 419 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, informs its shareholders... ► Artikel lesen | |
| 25.04.24 | Aelis Farma: Availability of the 2023 Universal Registration Document | 292 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces the publication... ► Artikel lesen | |
| 18.04.24 | Aelis Farma Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder | 334 | Business Wire | The last patient in the clinical phase 2b trial with AEF0117 for the treatment of cannabis use disorder has completed its last medical visit, paving the way for the release of study results in... ► Artikel lesen | |
| 02.04.24 | Aelis Farma Reports Its 2023 Annual Financial Results and Confirms Its 2024 Outlook | 417 | Business Wire | 2023 has been marked by key milestones for the Company's two drug candidates: AEF0117: completion of patient recruitment for the phase 2b study with 333 patients in excessive cannabis... ► Artikel lesen | |
| 30.01.24 | Aelis Farma Announces Its 2024 Financial Calendar | 509 | Business Wire | Regulatory News:
Aelis Farma (ISIN: FR0014007ZB4 Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain diseases, today announces its... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 50,48 | 0,00 % | Opening Bell: Netflix, Oracle, Procter & Gamble, ARM Holdings, Tempus AI, Constellation Energy | Nach dem Feiertag am Montag startete die Wall Street gestern äußerst freundlich in die Handelswoche. Der Dow Jones legte um 1,24 Prozent zu. Der S&P 500 verbuchte ein Plus von fast 0,9 Prozent und der... ► Artikel lesen | |
| QIAGEN | 46,035 | +0,98 % | Qiagen zahlt Ende Januar 1,26 US-Dollar je Aktie aus | VENLO (dpa-AFX) - Der Diagnostikspezialist und Labordienstleister Qiagen hat Details zu seinem sogenannten synthetischen Aktienrückkauf in Höhe von rund 300 Millionen US-Dollar bekanntgegeben. Je 36... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,490 | 0,00 % | Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth | ||
| SUMMIT THERAPEUTICS | 23,500 | 0,00 % | Why Summit Therapeutics Stock Is Jumping Today | ||
| SANA BIOTECHNOLOGY | 3,500 | 0,00 % | Sana Biotechnology (NASDAQ:SANA) Trading Down 6.5% - Here's Why | ||
| MODERNA | 37,235 | +6,87 % | Moderna-Aktie heute gut behauptet: Aktienwert steigt (34,8633 €) | Am US-amerikanischen Aktienmarkt notiert der Anteilsschein von Moderna aktuell fester. Der jüngste Kurs betrug 36,27 US-Dollar. Freuen können sich gegenwärtig die Aktionäre von Moderna: Das Wertpapier... ► Artikel lesen | |
| EVOTEC | 8,000 | +1,33 % | Chartanalyse: Evotec-Aktie: Es wird schon wieder kritisch! | © Foto: Christian Charisius/dpa - dpa-BildfunkIn der Aktie von Evotec ist es vor kurzem zu einem Kaufsignal gekommen. Das hat bislang aber keine Wirkung entfalten können. Der Chartcheck!Hinter den Evotec-Aktionären... ► Artikel lesen | |
| ABSCI | 4,025 | 0,00 % | Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside | ||
| METAGENOMI | 3,020 | 0,00 % | Metagenomi, Inc.: Metagenomi Highlights Progress Across Therapeutic Portfolio and Outlines Anticipated Milestones | MGX-001 in Hemophilia A Advances Towards US and Ex-US Regulatory Interactions in 2025 NHP Proof-of-Concept Anticipated for Secreted Protein Deficiency Platform in 2025 Leveraging MGX-001 Editing... ► Artikel lesen | |
| BIONTECH | 110,40 | -0,27 % | BioNTech Aktie: Geplante Maßnahmen und Strategien | Die BioNTech-Aktie zeigt sich in den ersten Januarwochen 2025 weitgehend stabil. Am Handelstag des 18. Januar verzeichnete das Papier einen leichten Rückgang von 0,74 Prozent auf 111,93 USD. Die Marktkapitalisierung... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,530 | +1,06 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| JANUX THERAPEUTICS | 40,250 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 30,020 | -2,66 % | Royal Bank of Canada Reiterates Outperform Rating for Avidity Biosciences (NASDAQ:RNA) | ||
| QUANTUM-SI | 2,380 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Showcases Advances in Multiomics at the Festival of Genomics UK | Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), The Protein Sequencing Company, announces its participation in the upcoming Festival of Genomics UK, taking place on... ► Artikel lesen | |
| ARCELLX | 65,87 | -1,05 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen |
AELIS FARMA SAS gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,980 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AELIS FARMA SAS finden Sie auf Wallstreet Online.
